

Index

Note: Page numbers of article titles are in **boldface** type.

A

Acute lymphoblastic leukemia, **1–19**

- genetic factors in, 1–6
- in Down syndrome, 54, 61–62
- relapse of, 74–77
- T-cell, 1, 5
- treatment of, 6–14
 - adolescents, 10–11
 - after relapse, 74–77
 - age factors in, 3–4
 - cardiovascular disease after, 256–257
 - central nervous system-directed, 6, 8
 - genomic techniques in, 11–12
 - host pharmacogenetics and, 14
 - immunophenotype and, 3–4
 - induction, 6–8
 - long-term effects of, 253
 - maintenance, 6–9
 - outcome of, 1–3
 - reinduction, 6, 8–10
 - side effects of, 11
 - stem cell transplantation in, 71–77
 - tailoring of, 2
 - targeted, 12–14
 - vaccinations and, 170–174

Acute myeloid leukemia, **21–51**

- clinical presentation of, 23–24
- core binding factor, 28, 33–34
- diagnosis of, 23–24
- epidemiology of, 21–22
- graft-versus-host disease in, 159–160
- in Down syndrome, 53. *See also* Myeloid leukemia of Down syndrome.
- pathogenesis of, 22–23
- prognosis for, 24–25, 32–36
- risk factors for, 21–22
- therapy-related, 82–83
- treatment of, 24–39
 - acute promyelocytic, 31
 - central nervous system-directed, 28–29
 - complications of, 38–39

- consolidation, 25–28
- in Down syndrome, 31
- induction, 25–28
- maintenance, 29
- minimal residual disease after, 36–37
- outcome of, 24–25
- pharmacogenomics of, 37–38
- prognosis for, 32–36
- relapsed, 31–32
- stem cell transplantation in, 29–31, 77–80
- supportive care in, 38–39

Acute promyelocytic leukemia, 31

Adolescents, acute lymphoblastic leukemia in, 10–11

Advance care planning, in palliative care, 227–228, 230–231

Adverse event recording and reporting, in clinical trials, 196–197

Age factors

- in acute myeloid leukemia, 32
- in neuroblastoma, 106

Alemtuzumab, for acute lymphoblastic leukemia, 13

ALL. *See* Acute lymphoblastic leukemia.

All-trans retinoic acid, for acute myeloid leukemia, 29

ALM gene mutations, acute myeloid leukemia in, 23

American Academy of Pediatrics, palliative care policy statement of, 224

AML. *See* Acute myeloid leukemia.

AML1 gene mutations, acute lymphoblastic leukemia in, 3–4

AML/ETO gene mutations, acute myeloid leukemia in, 23

Amsacrine, for myeloid leukemia of Down syndrome, 60

- Anemia, refractory, stem cell transplantation for, 81
- Angiogenesis
in neuroblastoma, 111
inhibitors of, for glioma, 132–133
- Anthracyclines
cardiotoxicity of, 28, 254–255
for acute lymphoblastic leukemia, 7
for acute myeloid leukemia, 24–28, 63
for Down syndrome leukemias, 63
for myeloid leukemia of Down syndrome, 59–60, 63
- Antigen-presenting cells, 149–150
- Apoptosis, in tumors, escape from, 155
- Asparaginase, for acute lymphoblastic leukemia, 7–8, 11
- Assent, pediatric, **211–222**
birth of, 212–213
child's role in, 214–215
complexity of, 216–217
decision-making models for, 215–216
elements of, 213
in oncology, 215
versus consent, 213
- Astrocytomas
cerebellar, 135
diffuse fibrillary, 133
juvenile pilocytic, 133
- Atherosclerosis, in long-term survivors, 255–256
- Atypical teratoid/rhabdoid tumors, 131–132
- Auditing, in clinical trials, 198
- Azoospermia, in long-term survivors, 259–260
- B**
-
- B cells, for cancer immunotherapy, 149–150, 156–157, 161–162
- BAALC* gene mutations, acute myeloid leukemia in, 36
- BACH1* gene mutations, myeloid leukemia of Down syndrome in, 65
- Bacille-Calmette Guérin vaccination, for immunocompromised cancer patients, 173, 176–177
- BCR-ABL* gene mutations
acute lymphoblastic leukemia in, 5, 12–13
acute myeloid leukemia in, 23
- Belmont Report, on ethics of human subjects in trials, 212–213
- Bereavement care, 229, 239–241
- Berlin-Frankfurt-Münster trial, of leukemia therapy
acute lymphoblastic, 73–74
acute myeloid, 25, 28–29
myeloid, of Down syndrome, 57, 59
- Best Pharmaceuticals for Children Act of 2002, 206–207
- Biologics Control Act of 1902, 205
- Blinding, in clinical trials, 202
- Bone marrow transplantation. *See* Stem cell transplantation.
- Brain stem, gliomas of, 123, 134–135
- Brain tumors, **121–145**
atypical teratoid/rhabdoid, 123, 131–132
choroid plexus, 139
classification of, 124–125
clinical presentation of, 122–123
craniopharyngiomas, 137–138
diagnosis of, 122–124
distribution of, 122
ependymomas, 123, 135–137
germ cell, 138–139
gliomas, 123, 132–135
long-term survivors of, 252–254
medulloblastomas, 123, 125–130
pineoblastomas, 131
risk factors for, 121–122
supratentorial primitive neuroectodermal, 130–131
- Busulfan
for myeloid leukemia of Down syndrome, 60
for stem cell transplantation preparation, 84–85
- C**
-
- Cancer. *See also* Leukemias; *specific types of cancer*.
central nervous system, **121–145**
clinical trials for
good clinical practice for, **187–209**
pediatric assent in, **211–222**
immune function influence of, 170
immunotherapy for, **147–167**
long-term survivors of, challenges in, **251–273**
neuroblastoma, **97–120**
palliative care for, **223–250**

Download English Version:

<https://daneshyari.com/en/article/4174409>

Download Persian Version:

<https://daneshyari.com/article/4174409>

[Daneshyari.com](https://daneshyari.com)